Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Alzamend Neuro Inc. is an innovative biotechnology company poised to revolutionize the treatment landscape for neurodegenerative diseases, especially Alzheimer's disease. Utilizing a proprietary drug development platform and a robust intellectual property portfolio, the company is strategically positioned to meet significant unmet medical needs in the pharmaceutical market. With a commitment to advancing its therapeutic candidates through rigorous clinical trials and fostering strategic partnerships, Alzamend Neuro aims to enhance patient quality of life and make substantial contributions to the neurotherapeutics sector. Its focused approach on critical neurological health challenges presents a compelling investment opportunity within the biotech industry.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$1.66
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Apr 30, 2026 Reported Jul 22, 2026 | $-0.67 | $-0.74 | Miss -10.4% | — | $0 | $0 | — | 1D Pre+4.8% | On-Day+2.3% | 1D Post-6.7% |
Q ended Jan 31, 2026 Reported Mar 11, 2026 | $-0.53 | $-0.58 | Miss -9.4% | $-0.58 | $0 | $0 | — | 1D Pre+1.9% | On-Day+1.9% | 1D Post-4.1% |
Q ended Oct 31, 2025 Reported Dec 9, 2025 | $-0.61 | $-0.30 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre0.0% |
| On-Day-3.6% |
| 1D Post-0.5% |
Q ended Jul 31, 2025 Reported Sep 10, 2025 | $-0.62 | $-1.28 | Miss -106.5% | — | $0 | $0 | — | 1D Pre+0.4% | On-Day-0.8% | 1D Post+2.1% |